Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scIgG) (SCIGG-H217)

Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD19 and anti-CD28 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD28

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scIgG) (SCIGG-H217). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD19 x Human Anti-CD28 Bispecific Antibody (scIgG) (CAT#: SCIGG-H217)

Specifications

Targets

Customer Reviews and Q&As